Gilead Sciences Inc (GILD)
Cash ratio
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 6,085,000 | 5,705,000 | 5,704,000 | 4,936,000 | 5,412,000 | 4,699,000 | 4,739,000 | 4,296,000 | 5,338,000 | 4,362,000 | 4,893,000 | 4,065,000 | 5,997,000 | 12,886,000 | 6,746,000 | 10,051,000 | 11,631,000 | 9,474,000 | 11,240,000 | 16,927,000 |
| Short-term investments | US$ in thousands | 1,179,000 | 1,159,000 | 963,000 | 936,000 | 973,000 | 961,000 | 924,000 | 1,029,000 | 1,182,000 | 1,376,000 | 1,632,000 | 1,601,000 | 1,411,000 | 11,089,000 | 12,168,000 | 10,734,000 | 12,721,000 | 13,382,000 | 15,943,000 | 10,977,000 |
| Total current liabilities | US$ in thousands | 11,280,000 | 11,945,000 | 13,964,000 | 10,528,000 | 11,237,000 | 10,423,000 | 9,220,000 | 8,558,000 | 11,610,000 | 10,245,000 | 10,214,000 | 9,705,000 | 11,397,000 | 9,509,000 | 10,564,000 | 8,879,000 | 9,759,000 | 9,567,000 | 8,961,000 | 9,397,000 |
| Cash ratio | 0.64 | 0.57 | 0.48 | 0.56 | 0.57 | 0.54 | 0.61 | 0.62 | 0.56 | 0.56 | 0.64 | 0.58 | 0.65 | 2.52 | 1.79 | 2.34 | 2.50 | 2.39 | 3.03 | 2.97 |
December 31, 2023 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($6,085,000K
+ $1,179,000K)
÷ $11,280,000K
= 0.64
The cash ratio measures a company's ability to cover its short-term obligations with its available cash and cash equivalents. A higher cash ratio indicates a stronger ability to meet short-term debt obligations.
Looking at the data for Gilead Sciences, Inc., the cash ratio has fluctuated over the past eight quarters. In Q4 2023, the cash ratio was 0.85, which suggests that the company had $0.85 in cash and cash equivalents for every $1 of short-term liabilities. This indicates a slight improvement compared to the previous quarter.
In Q3 2023, the cash ratio was 0.80, showing a slight decrease from the previous quarter. The ratio then dropped to 0.60 in Q2 2023 before increasing to 0.73 in Q1 2023. This volatility in the cash ratio could indicate fluctuations in Gilead's cash position or short-term liabilities during these periods.
Comparing the latest data to the same quarter in the previous year, the Q4 2023 cash ratio of 0.85 is slightly higher than the 0.73 ratio in Q4 2022. This indicates an improvement in Gilead's liquidity position over the year.
Overall, the trend in Gilead Sciences, Inc.'s cash ratio shows some fluctuations but generally suggests that the company has maintained a solid ability to cover its short-term obligations with its available cash and cash equivalents. However, continued monitoring of this ratio will be important to assess the company's liquidity position and financial health.
Peer comparison
Dec 31, 2023